PepGen, Inc. (NASDAQ:PEPG) Receives Average Recommendation of “Hold” from Brokerages

by · The Markets Daily

Shares of PepGen, Inc. (NASDAQ:PEPG – Get Free Report) have earned an average rating of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research analysts have recently issued reports on the company. Stifel Nicolaus increased their target price on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Guggenheim reissued a “buy” rating and set a $6.00 price objective on shares of PepGen in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PepGen in a research report on Wednesday, October 8th. Finally, HC Wainwright increased their price target on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th.

View Our Latest Stock Analysis on PepGen

PepGen Price Performance

Shares of NASDAQ PEPG opened at $5.66 on Tuesday. PepGen has a 1 year low of $0.88 and a 1 year high of $6.72. The stock has a market capitalization of $389.13 million, a P/E ratio of -2.01 and a beta of 1.91. The company’s 50-day moving average is $5.10 and its 200 day moving average is $2.87.

PepGen (NASDAQ:PEPG – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.11. Research analysts anticipate that PepGen will post -2.73 earnings per share for the current year.

Insiders Place Their Bets

In other PepGen news, major shareholder Science Enterprises Plc Oxford bought 200,000 shares of the firm’s stock in a transaction on Tuesday, September 30th. The stock was acquired at an average price of $3.20 per share, with a total value of $640,000.00. Following the completion of the purchase, the insider owned 4,955,388 shares of the company’s stock, valued at approximately $15,857,241.60. This trade represents a 4.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.20% of the company’s stock.

Institutional Trading of PepGen

Hedge funds have recently made changes to their positions in the stock. RBF Capital LLC bought a new position in PepGen in the 2nd quarter worth about $111,000. Adage Capital Partners GP L.L.C. raised its holdings in PepGen by 68.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock worth $1,897,000 after buying an additional 550,000 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of PepGen in the first quarter worth approximately $29,000. Nuveen LLC bought a new position in shares of PepGen in the first quarter worth approximately $139,000. Finally, XTX Topco Ltd purchased a new stake in shares of PepGen during the first quarter valued at approximately $25,000. 58.01% of the stock is owned by institutional investors.

About PepGen

(Get Free Report)

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

See Also